We replace clinical ambiguity with actionable, cell-level intelligence — analyzing locally enriched fluids from the eye to identify the cellular drivers of disease in living humans.
60% reduction in screening failures
Identify optimal trial candidates using molecular profiles, dramatically reducing screening failures and enriching enrollment for responders.
60% reduction in screening failures
55 → 75% projected Phase 3 P.O.S.
Data-driven enrichment strategy projects a meaningful increase in Phase 3 probability of success through biomarker-guided trial design.
55 → 75% projected Phase 3 P.O.S.
2× potential NPV increase
Scientifically defining the ideal patient population unlocks transformative asset economics — turning ambiguous programs into clear commercial wins.
2× potential NPV increase
Microvolume sample to actionable insight in 6–8 weeks.
| Step | Process | Description | Output |
|---|---|---|---|
| 01 | Microvolume Collection | Safely collect tiny fluid samples from aqueous humor or vitreous — minimally invasive, performed in the clinical setting. | <0.1 mL per sample |
| 02 | Proteomic Analysis | Detect and quantify approximately 6,000 unique proteins from a single sample using an FDA-validated aptamer-based assay. | ~6,000 proteins |
| 03 | Cellular Origin Mapping | TEMPO™ integrates proteomic data with single-cell transcriptomics, tracing each protein to its specific cellular origin. | Cell-level resolution |
| 04 | AI-Powered Insights | Proprietary machine-learning algorithms identify complex molecular signatures and develop novel biomarkers like "Molecular Age". | 6–8 week turnaround |
An intuitive, interactive dashboard that transforms complex proteomic data into actionable decisions for your clinical development team.
Confirm target engagement directly in human ocular samples.
Identify the molecular profile of likely "super-responders".
Track key biological processes longitudinally over time.
How We Deploy the Platform
Engage with us at any phase — or end-to-end. The Lazarus Effect re-opens stalled assets you may have already written off.
Phase 1 — Discovery
Apply the Molecure™ platform to retrospective samples from prior clinical trials to discover definitive molecular signatures correlated with strong therapeutic responses. We find what your trial data alone can't reveal.
Phase 2 — Validation
Prospectively validate the biomarker signature and engage the FDA through its Biomarker Qualification Program (BQP) to provide regulatory clarity and de-risk the path to approval.
Phase 3 — Enrichment
Leverage the FDA-qualified biomarker to design smaller, faster, and more efficient Phase 3 superiority trials enriched for the patients most likely to respond.
— Asset Rescue
Every major pharmaceutical company has a graveyard of promising candidates that failed to meet primary endpoints. By analyzing biobanked samples from these trials, we identify the shared proteomic signature of the patients who did respond — transforming a complete write-off into a de-risked asset ready for a biomarker-guided trial.
